There's more than enough Bob to go aroundBut now I'm not sure whether Denise or A.B. should get the main prize: "The Bob"? How do we decide?
Welcome to Phoenix Rising!
Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.
To become a member, simply click the Register button at the top right.
There's more than enough Bob to go aroundBut now I'm not sure whether Denise or A.B. should get the main prize: "The Bob"? How do we decide?
LDN has a large amount of support.
Since I skimmed all the patient comments, I don't deserve the Bob prize for such sloppy work, but here are my impressions:
Most comments are recommendations for research, some of them are very long and detailed. I would say that after the obvious recommendation to increase funding, the most popular recommendation is to prioritize development of diagnostic tests and research into biomarkers. ........
Overall this seems good. Patients have somewhat different priorities than the researchers but there is a large overlap in how they view the illness. NIH can't say they didn't get good feedback
I've only lightly skimmed a small section of the patient submissions so far. Autoantibodies, biomarkers, and subsetting are definitely addressed in various ways. I haven't seen IVIG and plasmapherisis specifically mentioned yet, but i hope they are. I'm not sure exactly what you mean by 'enecephalopathy', but I'm sure that the brain will have been mentioned.I hope that IVIG, plasmapherisis, autoantibodies, enecephalopathy, biomarkers, subsetting and others was addressed.
Interesting IACFS proposed biomarkers(9) & treatments(6) starting on page 25 of the researchers/clinicians section:I was glad that a number of researchers/clinicians took the time to provide input.
The patient/advocate/org input was generally quite thoughtful.
I was glad that a number of researchers/clinicians took the time to provide input.
As @A.B. noted "NIH can't say they didn't get good feedback"
It will be interesting to see the summary by NIH and interesting to see where they go from here.